About Creyon Bio
Creyon Bio is a Healthcare company based in San Diego (United States) founded in 2019 by Swagatam Mukhopadhyay. Oligonucleotide-based drug development platform is provided using AI models. The company has 20 employees. Its Indian entity Creyon Bio India Private Limited reported revenue of ₹14.09 Cr. Creyon Bio offers products and services including Oligonucleotide-Based Medicines and ASO Therapy. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Creyon Bio was founded in 2019 in San Diego, United States, within the biotechnology sector. A platform for drug design and oligonucleotide-based drug development is offered. Proprietary machine-learning and AI models are employed to create medicines targeting rare or common diseases. Operations focus on advancing therapeutic solutions through computational methods in the pharmaceutical industry.
- Headquarters San Diego, United States
- Employees 20
- Founders Swagatam Mukhopadhyay
- SectorsHealthcare
- Email••••••••
- Website creyonbio.com
- Social LinkedIn X
- Legal Name Creyon Bio India Private Limited
- Date of Incorporation 19 May, 2023
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹14.09 Cr
FY 2026 · +23% YoY
- Indian entity net profit₹1.61 Cr
FY 2026 · 11% margin
- Indian entity EBITDA₹2.41 Cr
FY 2026 · 17% margin
- InvestorsARE
& 4 more
- Employee Count20
Associated legal entities of Creyon Bio
Creyon Bio operates through Creyon Bio India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Creyon Bio India Private Limited CIN U72100KA2023FTC173910 | Active | 19 May 2023 | Bangalore South, Karnataka | ₹14.1 Cr | 2 | View details |
Products & Services of Creyon Bio
Creyon Bio offers a comprehensive portfolio of products and services, including Oligonucleotide-Based Medicines and ASO Therapy.
AI-engineered medicines for precise gene-centric disease treatment.
Therapy targeting genes to minimize off-target effects in diseases.
Funding Insights of Creyon Bio
- Total Rounds 2
- Investors Count 5
All 2 funding rounds of Creyon Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | Seed | – | DCVC, Lux Capital | ||
| Mar 2022 | Series A | – | DCVC, Lux Capital |
5 investors in total: 5 institutional.
Investors in Creyon Bio
Creyon Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, DCVC and Lux Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
| biobrit.com | ||||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Creyon Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Creyon Bio India Private Limited (Creyon Bio)
Creyon Bio India Private Limited is the primary company behind Creyon Bio. The board of Creyon Bio India Private Limited currently have 2 directors; the longest-serving is Jeyaprakash Narayanan Seenisamy, appointed in 2023. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jeyaprakash Narayanan Seenisamy DIN 10170495 | Director | 19 May 2023 | 3 yrs 5 mo | Creyon Bio India Private Limited |
| Priyanka Vijay Samji DIN 02816653 | Additional Director | 02 Jul 2026 | 4 mo | Creyon Bio India Private Limited |
People of Creyon Bio
25 people are tracked at Creyon Bio (9 in leadership, 6 in board & advisors, 10 in team); the tracked headcount is 20.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
Serge Messerlian | Board Member | Leadership |
Shaquille Vayda | Board Member | Leadership |
Carl Spickett | Director Of Translational Medicine | Leadership |
Nathan Billings | Chief Strategy Officer | Leadership |
Amy Bouck | Senior Director, Program Management & Corporate Development | Leadership |
Jason Ferrone | COO & General Counsel | Leadership |
Bret Malsnee | Sr Director Finance | Leadership |
Matthew Levy | VP, Exploratory Research | Leadership |
Manolis Kellis | Scientific Advisor | Board & advisors |
Barbara Englehardt | Scientific Advisor | Board & advisors |
Barbara Wold | Scientific Advisor | Board & advisors |
David Fajgenbaum | Advisor | Board & advisors |
Josh Wolfe | Director | Board & advisors |
Dennis Langer | Director | Board & advisors |
Jonathan Leung | Senior Software Engineer | Team |
Amanda Reyes | Scientist | Team |
Jamie Fagely | Manager, HR & Operations | Team |
Jesse Levitt | Senior Software Engineer | Team |
Chungwen Liang | Principal Scientist, Computation Science | Team |
5 more people are available in the full profile.
Complete people profiles for Creyon Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Creyon Bio
Figures of Creyon Bio India Private Limited, the primary company behind Creyon Bio, for FY 2026. Revenue was ₹14.09 Cr (+23% year on year). Net profit was ₹1.61 Cr (11% margin). EBITDA was ₹2.41 Cr (17% margin). Revenue has grown at a compounded annual rate of 0% over three years and 0% over five years.
- ₹14.09 CrRevenue · FY 2026 · +23% YoY
- ₹1.61 CrNet profit · 11% margin
- ₹2.41 CrEBITDA · 17% margin
- ₹1.30 CrPaid-up capital
- 0%Revenue CAGR, 3 years
- 0%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Creyon Bio India Private Limited are on its company page.
Detailed financial statements for Creyon Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Creyon Bio
2 dated milestones of Creyon Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Creyon Bio is founded.
- Funding First funding round.
Competitors of Creyon Bio
Creyon Bio has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Creyon Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Creyon Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Creyon Bio
Complete news archive for Creyon Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Creyon Bio
Creyon Bio was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Creyon Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Creyon Bio has 20 employees.
The primary company behind Creyon Bio, Creyon Bio India Private Limited, reported revenue of ₹14.09 Cr for FY 2026, up 23% year on year.
Creyon Bio was founded in 2019 in San Diego, United States, within the biotechnology sector. A platform for drug design and oligonucleotide-based drug development is offered. Proprietary machine-learning and AI models are employed to create medicines targeting rare or common diseases. Operations focus on advancing therapeutic solutions through computational methods in the pharmaceutical industry.
Creyon Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Creyon Bio offers Oligonucleotide-Based Medicines and ASO Therapy.
Creyon Bio has 5 investors. Key investors include ARE, DCVC, Lux Capital, Casdin Capital, and BioBrit.
Creyon Bio operates through Creyon Bio India Private Limited.
The legal entities of Creyon Bio currently have 2 directors, including Jeyaprakash Narayanan Seenisamy, Priyanka Vijay Samji.